首页 | 本学科首页   官方微博 | 高级检索  
检索        

2型糖尿病大鼠经不同干预后血浆内脏脂肪素水平的变化
引用本文:徐坤,何继瑞,张思功,胡彩虹,吴云霞.2型糖尿病大鼠经不同干预后血浆内脏脂肪素水平的变化[J].兰州医学院学报,2010,36(2):39-43.
作者姓名:徐坤  何继瑞  张思功  胡彩虹  吴云霞
作者单位:徐坤,张思功,吴云霞,XU Kun,ZHANG Si-gong,WU Yun-xia(兰州大学第二临床医学院,甘肃,兰州,730030);何继瑞,胡彩虹,HE Ji-rui,HE Cai-hong(兰州大学第二医院干部内科,甘肃,兰州,730030) 
摘    要:目的探讨2型糖尿病大鼠经不同干预后血浆内脏脂肪素水平的变化及其与空腹血糖(FPG)、空腹胰岛素(FINS)、胰岛素抵抗指数(HOMA)、总胆固醇(TO)、甘油三酯(TG)、高密度脂蛋白(HDL)、低密度脂蛋白(LDL)、游离脂肪酸(FFA)及体重的关系。方法采用高热量饲料加单次腹腔注射链脲佐菌素(35mg/kg)制备2型糖尿病大鼠模型,以1周后FPG≥11.1mmol/L为成模标准(n=28),将糖尿病大鼠分别予以瑞格列奈+二甲双胍(B,n=7)、罗格列酮十二甲双胍(C,n=7)、胰岛素+二甲双胍(D,n=7)、生理盐水(E,n=7)干预,8周末测定血生化指标并计算HOMA,采用ELISA法检测血浆内脏脂肪素水平。结果B—E组FPG、FINS、HOMA、TC、TG、LDL、FFA、内脏脂肪素及体重较对照组均显著升高(P〈0.01),HDL较对照组均明显下降(P〈0.01);给予不同治疗后FPG、FINS、HOMA较未治疗组明显下降(P〈0.05),C组FFA较其他各组明显下降(P〈0.05),而内脏脂肪素较其他各组明显升高(P〈0.051;相关分析及多元回归分析显示血浆内脏脂肪素水平与体重及糖脂代谢相关。结论过氧化物酶体活化增殖受体(PPARr)核受体可能参与调控内脏脂肪素的表达和分泌活动;内脏脂肪素可能是PPARr的激动剂药物治疗2型糖尿病的作用靶点之一;内脏脂肪素与糖脂代谢和体重密切相关,与胰岛素抵抗无关。

关 键 词:2型糖尿病  大鼠  内脏脂肪素  瑞格列奈  罗格列酮  二甲双胍  胰岛素

Changes of plasma visfatin level in rats with type 2 diabetes after different interventions
XU Kun,HE Ji-rui,ZHANG Si-gong,HE Cai-hong,WU Yun-xia.Changes of plasma visfatin level in rats with type 2 diabetes after different interventions[J].Journal of Lanzhou Medical College,2010,36(2):39-43.
Authors:XU Kun  HE Ji-rui  ZHANG Si-gong  HE Cai-hong  WU Yun-xia
Institution:1. School of Second Clinical Medicine, Lanzhou University, 730030 China; 2. Department of Geriatrics, Second Hospital of Lanzhou University, Lanzhou 730030, China)
Abstract:Objective To investigate the change of plasma visfatin level and the relationship between plasma visfatin level with fasting plasma glucose (FPG), fasting insulin (FINS), homeostasis model assessment (HOMA), total cholesterol (TC), triglyceride (TG), high density lipoprotein (HDL), low density lipoprotein (LDL), free fatty acids (FFA) and body weight to give different interventions in rats with type 2 diabetes. Methods With high-sucrose and high-fat diet+STZ (30 mg/kg) inducing Wistar rats, rats model with type 2 diabetes melitus was developed by means of FPG〉11.1 mmol/L (DM, n=28), and then given repaglinide+dimethylbiguanide (B, n=7),rosiglitazone+dimethylbiguanide (C, n=7), insulin+dimethylbiguanide (D, n=7), PS (E, n=7) in DM. Plasma visfatin levels were measured by ELISA in rats with type 2 diabetes and control after 8 weeks. The relationship of plasma visfatin level with FPG, FINS, HOMA, TC, TG, HDL, LDL, FFA and body weight were analyzed. Results FPG, FINS, HOMA, TC, TG, HDL, LDL, FFA, visfatin and body weight in diabetes rats and obese rats significantly increased and HDL significantly reduced compared with NC. FPG, FINS, HOMA in B-E groups significantly reduced compared with F. FFA in C group significantly reduced and visfatin level significantly increased compared with other groups. Correlation and multiple regression analysis showed that plasma visfatin level was closely correlated with glucolipid metabolism and body weight. Conclusion It is possible that peroxisome proliferator-activated receptors nuclear receptor joins in the express and secretory activity of visfatin. Visfatin, which is closely correlated with glucolipid metabolism and body weight, may be one of the targets of peroxisome proliferator-activated receptors excitomoter drug treat DM.
Keywords:type 2 diabetes mellitus  rat  visfatin  repaglinide  rosiglitazone  dimethylbiguanide  insulin
本文献已被 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号